News | Heart Failure | August 14, 2019

Ancora Heart Enrolls First Patient in European Multi-center Study of AccuCinch Heart Failure Therapy

Study will evaluate percutaneous therapy designed to improve left ventricular function for patients with systolic heart failure

Ancora Heart Enrolls First Patient in European Multi-center Study of AccuCinch Heart Failure Therapy

August 14, 2019 — Ancora Heart Inc. announced the first patient was enrolled in the CorCinch EU study, a European multi-center clinical evaluation of the AccuCinch Ventricular Repair System as a treatment for patients with reduced ejection fraction systolic heart failure (HFrEF).

The first patient was enrolled at Homolka Hospital in Prague, Czech Republic by Prof. Petr Neužil, M.D., CSc., FESC, head of the department of cardiology at Homolka Hospital and principal investigator of the study. The AccuCinch procedure was completed by co-investigator Vivek Reddy, M.D., director of cardiac arrhythmia services at The Mount Sinai Hospital in New York, along with Neužil.

“The transcatheter AccuCinch therapy is unique in its ventricular approach, which is intended to improve heart function by repairing the left ventricle for patients with systolic heart failure regardless of its origin,” said Neužil. “We are pleased to participate in this study because the AccuCinch has the potential to address the shortcomings of current medical, surgical and transcatheter treatments and restore quality of life and longevity for this large patient population.”

This is the second recently initiated Ancora study evaluating the AccuCinch system focused specifically on heart failure and the enlarged left ventricle. The study will enroll up to 132 patients from heart centers across Europe.

The transcatheter AccuCinch therapy is designed to complement and enhance the existing care cardiologists provide to further manage symptoms and slow, or stop, the progression of heart failure. For some patients, AccuCinch may have the potential to reverse the enlargement of the left ventricle. For patients where heart failure has progressed beyond the ability for medications and pacemakers to manage symptoms, non-surgical percutaneous device therapy with AccuCinch may provide an effective treatment option. The AccuCinch system is designed to directly repair the left ventricle of the heart, thereby addressing the fundamental issue in the progression of systolic heart failure.

An estimated 25 million adults worldwide live with heart failure, a condition in which the heart’s muscles slowly weaken and lose their ability to pump enough oxygen-rich blood to the body.1 Heart failure patients suffer from debilitating symptoms including persistent exhaustion, trouble breathing, confusion and loss of memory. About half of heart failure patients have an enlarged left ventricle, the main pumping chamber of the heart, which causes more stress on the heart and leads to reduced pumping efficiency. Current heart failure treatments only partially address the enlarged left ventricle and up to 50 percent of people who develop heart failure die within five years of diagnosis.1

For more information: www.ancoraheart.com

 

References

1. Benjamin E.J., Blaha M.J., Chiuve S.E., et al. Heart disease and stroke statistics—2017 update: a report from the American Heart Association. Circulation 2017; 135: pp. e146-e603

Related Content

FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
Overlay Init